New research suggests that targeting a particular cell signaling pathway with the diabetes drug metformin might offer a way to stop the progression and spread of pancreatic cancer.
The study — which was led by Rutgers Cancer Institute of New Jersey in New Brunswick — is to feature at the 2018 annual meeting of the American Association for Cancer Research, which will be held in Chicago, IL. Read more . . .